Abbott will collaborate with Janssen Biotech and Pharmacyclics to explore Abbott’s FISH (Fluorescence In Situ Hybridization) technology for the development of a molecular companion diagnostic test to identify patients with a genetic subtype of chronic lymphocytic leukemia (CLL), the most common form of adult leukemia.   Abbott will develop a FISH-based test to identify high-risk CLL patients that may respond to ibrutinib, an oral, small molecule inhibitor currently in development by Jansse...